DexCom, Inc. (DXCM)

DexCom (DXCM) fits the Growth at a Reasonable Price (GARP) strategy, offering strong earnings growth, reasonable valuation, and solid financial health as an affordable growth stock.

Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM) ... As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including DexCom (NASDAQ:DXCM) and its peers.

On Apr. 30, DXCM stock ... Q1 2026 earnings. The company’s revenue for the quarter amounted to $1.2 billion and surpassed the Street’s estimates. Moreover, its adjusted EPS for the period came in at $0.56, also topping Wall Street’s forecasts.

DXCM, a renowned medical device company and provider of CGM systems, has a market capitalization of $27.49 billion. It projects a 23.6% growth rate over the next five years and anticipates maintaining a strong performance going forward. DexCom’s earnings surpassed the Zacks Consensus Estimate ...

DXP Enterprises stock has delivered a very strong 5 year return, yet the current share price of US$157.98 still screens below an intrinsic value estimate based on a Discounted Cash Flow (DCF) model. This creates a clear tension between a powerful past run and what the valuation work suggests today.